Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 May 2019 | Story Zama Feni | Photo Charl Devenish
Dr Quinton Meyer and Marlena Visagie
National Control Laboratory Deputy Director, Dr Quinton Meyer (right), and Marlena Visagie, Quality Assurance Manager, at the laboratory within their facilities at the University of the Free State.

The University of the Free State-based National Control Laboratory for Biological Products (NCL) has maintained its esteemed status as a pharmaceutical testing laboratory after the South African Accreditation System (SANAS) further endorsed its quality-management systems as of high standard according to the International Standards Organisation’s requirements.

The Director of the NCL, Professor Derek Litthauer, said their laboratory – which is also approved by the World Health Organisation (WHO) – has again achieved the international testing standards. The cherry on top was that the NCL also received a certificate of Good Manufacturing Compliance (GMP) from the South African Health Products Regulatory Authority (SAHPRA). 

NCL is for Africa and the World 

Some of the factors that make the NCL an esteemed institution, is the fact that it is one of 12 laboratories worldwide to perform vaccine testing for the WHO; the NCL is the only vaccine-testing laboratory in the country that performs the final quality-control testing of all human vaccine batches marketed in South Africa on behalf of SAHPRA. 

For example, Prof Litthauer said that the influenza vaccine batches currently available on the South African market, were tested by the NCL for quality before authorising their release for sale to the public. This process is followed for all human vaccines used in SA.

 “In our role as vaccine-testing laboratory for the WHO, the NCL helps to ensure that the vaccines purchased through the WHO prequalification programme for international distribution to resource-limited countries, meet the high standards of quality, safety, and efficiency. 
The NCL was one of the first full members of the WHO NCL Network for Biologicals, which consists of full and associate members of regulatory authorities from more than 30 countries.

The NCL systems are world-class

Prof Litthauer said this achievement is recognition that their laboratory complies with specific international standards with respect to its quality-management system. 
“In practice, it means that the laboratory has all the quality systems in place to ensure high-quality test results. The GMP certification is a further step, meaning that laboratory testing is on the expected level for any pharmaceutical testing laboratory and manufacturer. It is a very strict certification.”

He further mentioned that the NCL is also licensed as a pharmaceutical manufacturer. “Although we do not manufacture, we have to comply with manufacturing standards.”
“It is rare for a pharmaceutical testing laboratory (such as the NCL) outside of a manufacturing context to qualify for both certifications. It means that the NCL complies with exceptionally strict standards for pharmaceutical labs anywhere in the world,” he said.
The certification provides the South African Health Products Regulatory Authority, the World Health Organisation, and other national control laboratories around the world, with the confidence that the test results from the NCL can be trusted.


There can be no compromise for quality 

The NCL Quality Assurance Manager, Mrs Marlena Visagie, said, “It is essential that the NCL complies with the highest international quality-assurance standards to ensure that all the lot-release operations, such as manufacturing review and quality testing, are performed in a reliable and reproducible manner.”

“There can be no compromise when it comes to the quality of medicines which are made available to the public,” she said.

“What makes this special, is that the NCL does not only comply with international ISO/IEC standards for pharmaceutical testing, but also with the additional GMP standards required by a pharmaceutical manufacturer. This means that the NCL must ensure that all its operations, including everything from the way documents are compiled and stored, to the maintenance of equipment and infrastructure as well as staff competency, are performed according to international guidelines.”

All NCL staff share vision of excellence

Prof Litthauer said the NCL has a staff complement of 15 technical, administrative, and support staff.  Four staff members have PhDs, and the rest of the technical staff have master’s or bachelor’s degrees or are trained as medical technologists. “At the moment, our biggest problem is to get enough suitable space to expand our testing,” he said.

Prof Litthauer said, “All the staff members at the NCL share the vision of excellence, which makes this kind of achievement possible.”
The NCL will host the third annual meeting of the WHO NCL Network in November of this year and will then be reassessed again by the WHO as part of the normal three-year cycle of assessments.  

News Archive

Free State Receives R7 Million Grant from the Mellon Foundation for Arts Innovation
2015-11-30


Man in the Green Blanket, Lesiba Mabitsela.
Photo: Karla Benade

Bloemfontein will experience a flood of new, experimental art over the next four years as a result of R7 million that has been received to develop experimental art projects in central South Africa. The Andrew W. Mellon Foundation recently awarded the grant to the University of the Free State (UFS) for the Programme for Innovation in Artform Development (PIAD). Initiated jointly by the UFS and the Vrystaat Arts Festival in 2014, PIAD was established as a programme to promote the exploration of the arts to advance interdisciplinary research and to impact on human development.

The Andrew W. Mellon Foundation is a New York-based, non-profit organisation which endeavours to strengthen, promote, and, where necessary, defend the contributions of the humanities and the arts to human flourishing, and to the well-being of diverse and democratic societies.

“The Innovation in Artform Development initiative will provide an important contribution to the ways in which the university hopes to broaden and deepen research and dialogue about the humanities in South African society. Using the arts as a vehicle to engage communities around issues of social significance, makes for an exciting endeavour, and we are happy to have Mellon’s financial and partnership investment in this initiative,” said Prof Jonathan Jansen, Vice-Chancellor of the UFS.

“This substantial support from the Foundation will play a pivotal role in facilitating collaborations with national and international artists to explore new, innovative modes of artistic practice and creative production in South Africa,” said Angela de Jesus, UFS Art Curator and Co-Director of PIAD.

“A series of First Nations projects, arts/science research and artist residencies, arts laboratories for creative practitioners, the production of exciting new work for Bloemfontein, and critical debates/forums is expected over the next few years,” she added.

PIAD focuses on supporting cross-cultural, experimental art programmes that can assist South African society creatively. For this process, PIAD is engaging the skills and expertise of South Africa artists in collaboration with several international partners, who are recognised as global leaders in this field, to develop a mutually- beneficial programme of engagement.  

Innovation, technology, and new forms of art will be explored and international collaborations that have the potential to attract benefits for the creative industries in Bloemfontein and beyond will be introduced.

“The artistic landscape of the Free State - in fact the whole South Africa - will be forever changed because of this extraordinarily generous grant. Rarely does a regional community get a chance to lead innovation on a national scale, and also impact on experimental art internationally. We are in for an incredible artistic journey,” said Dr Ricardo Peach, Director of the Vrystaat Arts Festival and Co-Director of PIAD.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept